Shares of BioAge Labs Inc. (BIOA) touched a new 52-week high of $16.18 during intraday trading yesterday, implying a gain of over 115% in just two months.
The company's lead drug candidate is BGE-102, a potent, structurally novel, orally available, brain-penetrant small molecule NLRP3 inhibitor, being developed for the treatment of patients with cardiovascular risk factors.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com